Marshall Wace North America’s Rhythm Pharmaceuticals RYTM Stock Holding History

Marshall Wace North America’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-169,156	Closed	-$3.6M	–	1727
2021 Q1	$3.6M	Buy	+169,156	New	+$4.91M	0.01%	648
2020 Q4	–	Sell	-70,632	Closed	-$1.53M	–	1549
2020 Q3	$1.53M	Sell	70,632 -230,936	-77%	-$5.29M	0.01%	672
2020 Q2	$6.72M	Buy	+301,568	New	+$5.88M	0.04%	326
2019 Q2	–	Sell	-1,195	Closed	-$33K	–	1548
2019 Q1	$33K	Buy	+1,195	New	+$34.3K	﹤0.01%	1326
2018 Q3	–	Sell	-137,971	Closed	-$4.31M	–	1313
2018 Q2	$4.31M	Buy	137,971 +125,138	+975%	+$3.42M	0.02%	553
2018 Q1	$255K	Sell	12,833 -20,753	-62%	-$551K	﹤0.01%	1292
2017 Q4	$976K	Buy	+33,586	New	+$888K	0.01%	996

Other funds holding RYTM

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Marshall Wace North America's RYTM Position: Q2 2021 in Review

Marshall Wace North America sold out of Rhythm Pharmaceuticals (RYTM) in Q2 2021, closing a stake of 169,156 shares — an estimated $3.6M sold.

Marshall Wace North America first reported a position in RYTM in Q4 2017 and held it in 7 quarters. The position peaked at $6.72M in Q2 2020. 105 funds tracked by Wall St. Rank hold RYTM as of Q2 2021.

Marshall Wace North America reported no remaining Rhythm Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Marshall Wace North America sold 169,156 Rhythm Pharmaceuticals shares in Q2 2021, an estimated $3.6M.
Marshall Wace North America first reported a position in Rhythm Pharmaceuticals in Q4 2017 and held it in 7 quarters.
Marshall Wace North America's Rhythm Pharmaceuticals position peaked at $6.72M in Q2 2020.
105 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2021.

Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.